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Cancer treatments can induce premature ovarian failure in almost half of young women suﬀering from invasive neoplasia.
Cryopreservation of ovarian cortex and subsequent autotransplantation of frozen-thawed tissue have emerged as promising
alternatives to conventional fertility preservation technologies. However, human ovarian tissue is generally harvested before the
administration of gonadotoxic treatment and could be contaminated with malignant cells. The safety of autotransplantation of
ovariancortexremainsamajorconcernforfertilitypreservationunitsworldwide.Thispaperdiscussesthemaintoolsfordetecting
disseminated cancer cells currently available, their limitations, and clinical relevance.
1.Introduction
Thanks to progress made in the ﬁeld of cancer treatments,
long-term survival of patients has increased considerably
overthelastdecade.Unfortunately,someofthesetreatments,
such as chemo- and radiotherapy, can induce premature
ovarian failure. It has been determined that nearly half of
women diagnosed with invasive cancer will face premature
ovarian failure [1]. Consequently, fertility preservation in
reproductive-age women has become a major concern in
oncology units during the last decades. However, many
patients cannot beneﬁt from classic fertility preservation
technologies for medical and/or personal reasons. Cryop-
reservation of ovarian tissue by slow-freezing followed by
autotransplantation of thawed tissue provides an alternative
method for fertility preservation in young women and even
prepubertal girls [2]. While the exact number of ovarian tis-
sue autotransplantations performed worldwide is unknown,
this procedure has resulted in 13 reported births of healthy
children [3], including two in our centre [4, 5].
Despite these encouraging results, human ovarian cortex
autografts still present some major limitations. A major
concern is the possibility of reintroducing malignant cells
into the patient. Indeed, as the ovarian biopsy and cryop-
reservation procedures are ideally performed prior to the
administration of chemo- or radiotherapy, there is a risk of
ovarian involvement and subsequent retransmission of the
disease after autotransplantation. In a Japanese retrospective
study performed on autopsy specimens, 22,4% of cancer
patients under the age of 40 had ovarian metastases [6].
Most of the metastases aﬀecting ovaries are derived from
the gastrointestinal tract, breast cancer, or endometrial
cancer [7–9]. It can be argued that these individuals are in
advanced stages of the disease compared to women beneﬁt-
ing from ovarian tissue cryopreservation, but this underlines
the fact that metastases can be found inside the ovarian
tissue of young women. In fact, little is known about the
presence of malignant cells inside the graft and the risk of
neoplasia retransmission after autotransplantation of cryop-
reserved ovarian tissue. Of the 13 live births reported in the
literature, the autotransplanted frozen-thawed ovarian tissue
was derived from 8 cancer patients and two patients treated
for benign disease [3]. Among these cancer patients, 4 had
Hodgkin’s lymphoma (HL), one had breast cancer, one had2 Obstetrics and Gynecology International
non-Hodgkin’s lymphoma (NHL), one had Ewing sarcoma,
and one had neuroectodermic tumour. To date, there are
no reports of disease recurrence following the procedure.
However, using a mouse lymphoma model, it has been
established that lymphoma can be transmitted through the
graft even after cryopreservation and thawing of the ovarian
tissue if cancer cells are present in the ovary [10]. Lymphoma
can be contracted even with one small piece of ovarian tissue
(∼1mm 3) containing cancer cells [10] .T h es a m er e s u l t s
have been observed for leukaemia in a rat testis model [11].
In this study, fresh or frozen-thawed testicular cells from
leukemic rats were injected in the testis of recipient rats.
All of the recipient animals developed signs of leukaemia
although a 3–6 day delay was observed in the appearance of
symptoms in the frozen-thawed cell transplantation group
[11]. Interestingly, it was also demonstrated that only 20
leukemic cells were suﬃcient to cause leukaemia after 3
weeksin60%oftheanimals[11].Thesetwostudiesillustrate
that malignant cells from haematological cancer can induce
relapse in cured patients if these cells are present in the
ovarian tissue. Additionally, these results provide evidence
that cancer cells are resistant to freezing-thawing process.
The safety of ovarian tissue transplantation in cancer
patients should thus be addressed systematically for malig-
nancies with low-to-moderate risk of ovarian implication.
Herein,wewilldiscussthemaintoolsthatarecurrentlyavail-
ableforthedetectionofdisseminatedcancercells,speciﬁcally




In our centre, more than 30% of indications for ovarian tis-
sue cryopreservation concern young patients aﬀected by
breast neoplasia. Others have also reported breast cancer as
the main indication for fertility preservation [12, 13]. In
these cases, the risk of ovarian metastases is considered low
to moderate (0.2% to 11%) [14]. Unfortunately, there is
no established method for the detection of cancer cells in
ovarian tissue. Only a few recent studies have analysed the
incidence of ovarian metastasis in breast cancer patients who
underwentcryopreservationprocedure[15–17].Theauthors
investigated the presence of breast cancer cells by histology
and immunohistochemistry in more than 160 ovarian cortex
biopsies originating from 133 women entering the fertility
preservation program. One of these studies [17]f o c u s e d
on gross cystic disease ﬂuid protein-15 (GCDFP15) and
mammaglobin-1 (MGB-1), two speciﬁc markers of breast
epithelium that are not normally expressed in ovarian tissue
[18–20]. In two additional studies, the authors used broad
spectrum cytokeratin (CK) antibodies [15]o rC K - 7 ,C K -
aecam and markers of ovarian epithelium [16]. In these
studies, there was no evidence of malignant inﬁltration of
the ovarian tissue, even in patients with local lymph-node
involvement, which were 44% of the cases in the Rosendahl
et al. study. The authors prudently concluded that ovarian
tissue preservation seems to be a safe procedure in women
with early stages of breast cancer, but “new methods of cancer
screening may change their perception of this procedure”[ 17].
Similarly,aseriesofovariancortexoriginatingfrom28breast
cancerpatientsbeneﬁtingfromthefertilitypreservationpro-
gram in our centre were analysed by immunohistochemistry.
The histology and CK-19 staining revealed no invasion
of ovarian tissue by metastatic cells of mammary origin
(personal data).
Haematologic malignancies are also reported as a fre-
quent indication for ovarian tissue cryopreservation [21].
In lymphoma cases, the risk of residual disease in the
ovary was particularly highlighted by the Shaw et al. study,
which reported that ovarian tissue collected from mice with
lymphoma could transfer the disease to healthy recipient
animals [10]. Many authors have thus addressed the safety
of ovarian tissue autotransplantation in lymphoma patients.
In addition to ovarian biopsies from patients beneﬁting from
ovarian tissue autotransplantation, ovarian tissues from 79
patients with HL were analysed and demonstrated no his-
tological evidence of malignant contamination [22–25]. The
same analysis was performed on the ovarian tissue of NHL
patients and did not reveal any ovarian involvement either
[22, 24]. Moreover, in xenograft experiments of ovarian
tissue from both HL and NHL patients, none of the grafted
animalsdevelopedthedisease[22].Asaconsequenceofthese
analyses, the autotransplantation of frozen-thawed ovarian
tissue originating from lymphoma patients is currently
considered safe [26–29]. In the case of leukaemia, the risk
of disease retransmission is much more signiﬁcant because
malignant cells may be present in the patient bloodstream
at the time of tissue retrieval. Surprisingly, histological
examination of ovarian biopsies from leukaemia patients
reveals no invasion of the tissue. In contrast, more sensitive
methods of detection have determined that this tissue is,
in fact, contaminated by leukaemia cells [21, 24, 30]. This
illustrates the limitations of histology and immunohisto-
chemistry in terms of sensitivity of detection. Moreover,
these methodologies only examine a small part of the tissue,
and,therefore,arenecessarybutnotsuﬃcienttoestablishthe
safety of ovarian autotransplantation in cancer patients. As
a result of these limitations, complementary approaches to
improve the detection of metastatic disease in ovarian tissue
are being developed. As discussed below, polymerase chain
reaction (PCR) oﬀersseveraladvantagesinthiscontextwhen
used in state of the art.
3.MolecularAnalysisof OvarianTissue
Numerous studies detailed above were carried out using
only classic histology and immunohistochemistry. However,
several recent studies used a complementary molecular ap-
proach to improve the sensitivity of detection for dissemi-
natedcancercells.Indeed,quantitativereversetranscription-
polymerase chain reaction (RT-PCR) has a high sensitivity
and speciﬁcity of disseminated cancer cell detection, one
cancer cell in up to 107 normal cells, and can be applied
to virtually all types of cancer if adequate tissue or cancer-
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such as leukaemia and NHLs, molecular markers for assess-
ing minimal residual disease can often be identiﬁed. In
general, these markers are an immunoglobulin gene rear-
rangement in B-cell lymphoma, a T-cell receptor gene rear-
rangement in T-cell lymphoma, the BCR-ABL (breakpoint
cluster region-Abelson) translocation in chronic myeloid
leukaemia (CML), or translocations and mutations in acute
lymphoblastic leukaemia (ALL). For these diseases, markers
are often, but not always, available, and this approach has
beenusedbyseveralteamsonovariantissueforthedetection
of leukaemia and lymphoma cell contamination [21, 24, 30].
In the Dolmans et al. study, no malignant cells were detected
by histology in the ovarian tissue of six patients with CML
and 12 patients with ALL, whereas ovarian tissue in 33% of
CML patients and 70% of ALL patients were found to be
positive by quantitative RT-PCR [21]. Moreover, xenograft
experiments showed leukemic invasion of grafts originating
from 5/12 ALL patients [21] .T h es a m ec o n c l u s i o n sw e r e
made in another study in which histology and multimarker
immunohistochemical analyses were both negative for the
presence of malignant cells, whereas disease-speciﬁc genetic
markers were detected by quantitative RT-PCR in 6 of 8
patients with CML or ALL [30]. These results demonstrate
the presence of residual disease in a high percentage of the
ovarian biopsies from patients with leukaemia, which sug-
gests that autotransplantation of frozen-thawed ovarian
tissue in these patients is not safe.
Surprisingly, although breast cancer constitutes the
major indication for ovarian tissue cryopreservation in sev-
eral centres, no molecular analyses of the presence of dis-
seminated breast cancer cells in ovarian tissue have been
reported todate. Asthe safetyofovarianautotransplantation
in breast cancer women remains a major concern, we have
initiated the validation of quantitative RT-PCR markers spe-
ciﬁc to breast epithelium using the same method employed
for the detection of metastatic cells in the sentinel node.
We attempted to evaluate ovarian tissue contamination
by metastases of mammary origin and the presence of
circulating mammary tumour cells (CTCs) in the peripheral
bloodofpatientsretrievedatthetimeofthecryopreservation
procedure. Indeed, the presence and number of CTCs are
ap o o rp r o g n o s t i cf a c t o ri nt e r m so fr e l a p s e ,s u r v i v a l ,a n d
the presence of micrometastases in several solid neoplasias
including breast cancer [31]. Several molecular markers
permitting the detection of mammary CTCs by RT-PCR
have been described in the literature [32, 33], and we have
evaluated the sensitivity and speciﬁcity of ﬁve of them for
the detection of CTCs in peripheral blood and disseminated
tumour cells (DTCs) in ovarian tissue. Unfortunately, while
the majority of these markers are useful for the detection
CTCs,noneofthemareusefulforthedetectionofmammary
micrometastases inside the ovarian cortex due to their strong
basal expression in normal tissue (personal data). Additional
investigations are necessary to evaluate whether these pos-
itive signals are the result of illegitimate transcription or
normalexpressionintheovarianepithelium.Toidentifynew
mammary molecular markers that could be used in ovarian
tissue, it would be interesting to explore a group of small
noncodingribonucleicacids(RNAs),calledmicro-RNA(mi-
RNAs). Indeed, some mi-RNAs are expressed in a tissue-
speciﬁc manner and can be diﬀerentially expressed between
tumours and normal tissues [34]. These characteristics could
be very useful for the detection of disseminated breast cancer
cells and also in other neoplasias.
Despite the sensitivity and the fact that this molecular
tool can theoretically be applied to all malignancies, quan-
titative RT-PCR detection of disseminated cancer cells inside
ovarian tissue is not devoid of limitations. Indeed, extracting
RNA from this dense and ﬁbrous tissue is challenging and,
the results obtained from this analysis are highly dependent
on the quality of RNA extracted and the eﬃciency of cDNA
synthesis. We have also noticed that genetic markers are
not always available for all patients, particularly for ALL
patients. In addition, illegitimate transcription has been well
describedandcouldleadtofalsepositives.Finally,theclinical
relevance of a positive signal inside ovarian tissue has not
been established yet. Therefore, further studies are required
to evaluate if cancer cells detected in thawed ovarian tissue
areviableandthetransplantabilitythresholdofthesecells.As
discussed below, xenograft experiments can partially address
these last issues.
Inconclusion,itisnowclearthatthedetectionsensitivity
of disseminated cancer cells can be increased by the use
of molecular detection tools, such as quantitative RT-PCR.
However, this technique should not be used alone in this
context, but only in combination with other detection tools,
like immunohistochemistry and/or xenografting.
4. Xenotransplantation, a Tool
toEvaluatetheSafetyof OvarianTissue
AutotransplantationinCancer Patients
The ﬁrst clinical attempts at xenotransplantation date back
to the 17th century when blood from animals was used
to transfuse humans in France and England [35]. In the
19th century, tissues (mainly the skin) and during the
20th century, vascularised organs were attempted to be
grafted into humans without success [35]. The reason for
these failures was the acute rejection of the transplanted
tissue by the immune system [36]. The development of
transgenic immunotolerant animal models allowed xeno-
transplantation to have new insights in the research ﬁeld.
Today, some mice strains have mutations that make them
suﬃciently immunodeﬁcient to permit xenotransplantation
[36]. Among them, nude mice that are athymic, and thus
T-cell deﬁcient, [37] and severe combined immunodeﬁcient
mice (SCID) carrying an autosomal recessive mutation
that severely aﬀect lymphopoiesis, which makes mice that
are homozygous for this mutation deﬁcient in B and T
lymphocytes [38], are the most frequently used for ovarian
tissue xenografts. Many sites have been used for ovarian
cortex xenografts, including subcutaneous sites, the bursal
cavity, under the kidney capsule, or in the muscle [39–47].
As a risk of reintroducing cancer into remission patients
is theoretically possible following autotransplantation of
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cortical tissue to immunodeﬁcient animal hosts has been
suggested as an alternative to assess the safety of the proce-
dure. Xenotransplantation models have initially focussed on
studying ovarian follicular development, in which primor-
dialfolliclesareactivatedinanimmunocompromisedanimal
model and, after initial growth, are transferred to an in vitro
culture system [36]. This approach eliminates the risk of
cancer cell reintroduction, and, additionally, the problem-
atic unaccomplished phase of primordial follicle culture is
bypassed [36]. Unfortunately, the use of xenotransplantation
to mature follicles “in vivo” is still not ready to be used in
clinical applications, as its safety and ethical issues have yet
to be discussed [48].
The use of xenotransplantation to evaluate the risk of
reintroducing malignant cells is quite recent [22]. The ﬁrst
in vivo evaluation of residual disease using xenograft models
was studied in HL and NHL [22]. No clinical sign of the
disease and no microscopic evidence of residual disease
were found in animals xenografted with ovarian tissue from
patients diagnosed with HL or NHL [22]. Although these
results are quite reassuring, they cannot be interpreted as
absolute evidence of safety. Some years later, ovarian tissue
xenotransplantation to immunodeﬁcient mice was used to
evaluate the risk of reintroducing leukaemia, in parallel with
histologyandquantitativeRT-PCR[21].Infact,asleukaemia
is considered as a systemic cancer, malignant cells may be
present in the bloodstream and can thus easily migrate to
theovary.Furthermore,aretrospectiveanalysisofanautopsy
study demonstrated leukemic invasion of the ovaries in 8,4%
of patients [6]. After long-term xenografting (6 months) of
frozen-thawed ovarian tissue from patients with CML and
ALLintoSCIDmice,onethirdofthemicegraftedwithtissue
from ALL patients showed massive macroscopic peritoneal
invasion [21]. No malignant cells were microscopically
identiﬁed in grafts retrieved from mice transplanted with
ovariantissuefromCMLpatients;however,obviousinvasion
of lymphoblasts was observed in 5 of the 12 mice grafted
with ovarian tissue from ALL patients [21]. These results
are quite alarming considering all ovarian tissues that were
determinedbehealthyanddisease-freefollowinghistological
analysisprecedingthexenograft.Moreover,onlyhistological,
and eventually immunohistochemical, analysis is routinely
performed prior to autotransplantation of ovarian tissue in
ac u r e dp a t i e n t .
More recently, the safety of ovarian tissue autotransplan-
tation from patients with ovarian tumours was investigated
using xenografting to SCID mice [49]. After 24 weeks, no
sign of malignancy was detected either macroscopically or
histologically [49]. Despite these reassuring results, the risk
of reintroducing malignant cells in cases of ovarian cancer
is considered high, as bilateral carcinoma is found in ap-
proximately 25% of all ovarian cancers [50].
Regarding breast cancer, no study using a xenograft
model has been published to date. The ﬁrst evaluation by
histologyandimmunohistochemicalanalysisshowednosign
of metastases [16, 17]; however, further investigations, using
xenograft models, for instance, are still required to conﬁrm
the safety of the procedure in breast cancer patients.
5. Conclusion
Itis now clearthat cryopreserved ovarian tissuemay harbour
malignantcellsthatcouldprovokerelapsefollowinggrafting.
Currently available data suggest that autotransplantation of
frozen-thawed ovarian tissue is a safe procedure for patients
with Hodgkin’s disease at the time of ovarian biopsy [26–
29]. Indeed, there is no evidence of ovarian involvement in
the ovarian cortex of patients undergoing cryopreservation.
Moreover, no relapse has been reported in patients after
ovarian autotransplantation and spreading to the ovary has
only been described in extremely rare cases [51]. However,
even though these results are reassuring, it does not mean
that there are no risks associated with autotransplantations.
Moreover, the safety of the procedure has not yet been es-
tablished for all other malignancies. If it is clear that
autotransplantation of ovarian tissue cannot be proposed
for leukemic patients, precautionary decisions have to be
taken for all other patients [21, 24, 30]. In the case of
other neoplasias, and in particular for breast cancer patients,
additional strategies must be developed to determine the
safety of this procedure. This implies the identiﬁcation
of (breast) cancer molecular markers that are usable in
ovarian tissue and xenograft experiments. We believe that
quantitative RT-PCR, despite its limitations, is a promising
tool for the detection of micrometastases inside ovarian
tissue.Additionally,xenotransplantationstudiesinimmuno-
tolerant mice provide additional information concerning
putative ovarian involvement.
However, these tools are not perfect for the detection
of micrometastases as they also have some disadvantages. A
major limitation of RT-PCR is the interpretation of positive
results. Indeed, it has been shown that BCR-ABL mRNA can
be detected at very low levels in healthy patients [52, 53].
Similarly, a recent study showed that leukemic markers can
be detected in ovarian tissue from ALL patients; however,
some mice xenografted with this tissue did not develop neo-
plasia [21]. As expected, none of the mice grafted with PCR-
negative tissue developed leukemic progression either [21].
A potential limitation of xenotransplantation experiments
is that a lack of tumour growth in recipient mice could be
explainedsimplybytheabsenceofmalignantcellsinthevery
small piece, usually 1mm3 or less, of ovarian cortex typically
usedforthegraft,whereasmalignantcellscouldbepresentin
the rest of the cryopreserved tissue. Indeed, the distribution
of malignant cells in the tissue is not homogeneous or
uniform. It is therefore of major importance to standardise
detection techniques of residual malignant cells and to assess
their clinical relevance. To accomplish this, it would be
interesting to develop a multicentric and multidisciplinary
approach combining molecular and xenograft analyses for
pathologies with low-to-moderate risk of ovarian invasion.
For cancer patients who cannot beneﬁt from ovarian tissue
autotransplantationduetotheriskofdiseaseretransmission,
alternatives such as in vitro follicle culture [54] and isolated
follicles transplantation [55] are promising approaches.
However, these alternatives are still in the early stages, and
huge research eﬀorts need to be conducted prior to clinical
implementation.Obstetrics and Gynecology International 5
In conclusion, the decision to graft a patient or not must
involve a multidisciplinary discussion involving oncologists,
gynaecologists, anatomopathologists, and molecular bi-
ologists. It is essential to balance the risks and beneﬁts for
each patient and remain extremely cautious regarding ovar-
ian cortex autotransplantation. We should keep in mind
that although recovering fertility is very important to some
patients, reimplantation of contaminated ovarian tissue
could be a life-threatening event.
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